Watch for spinout...Orethecin will be combined with another Supg drug pipeline and enter Phase II. I believe we hear about a partnership involved in this deal. Supg has several pipeline drugs that target Pancretic cancer. I believe with CLIMB technology they were able to identify and improve Orethecin. Do your research and listen to conferences. CEO has given this info serveral times....look for update late Dec. or early first quarter. 2007 looks like we will get PR support the stock requires to hold gains. Supg hands are tied because of partnerships and that's just how it goes. In the background JNJ and MGI are spending money $...and that data is just around the corner. If you have watched SUPG and spent anytime reviewing their web site...then why is Orethecin listed as a phase II drug now...was a phase III drug on their web page for a long time. Move it back to phase II and combine it with pipeline drug. Looks to me that Montigen not only brought to the table the second generation MDS drug....but just maybe the answer to getting Orethecin approved? Just speculation here....but something for this board to think about.
News here soon. Combination was the key to maybe unlock approval. December 20...Mayne pharma vote unless delayed. Sometime in the first quarter SUPG recognizes 26.2M on Nipent sale. Think we see 5.25 by 12/31/06.